Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke

Basit Öğe Kaydı
dc.authorwosidDuran, Rıdvan/C-1065-2015
dc.contributor.authorDuran, R
dc.contributor.authorBiner, B
dc.contributor.authorDemir, M
dc.contributor.authorÇeltik, C
dc.contributor.authorKarasalihoglu, S
dc.date.accessioned2024-06-12T11:07:18Z
dc.date.available2024-06-12T11:07:18Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the association between ischemic childhood stroke and thrombophilia. The prevalence of thrombophilia risk factors in 30 unrelated children with ischemic stroke were compared with 33 age-matched control subjects. Patients and control group were tested for the presence of activated protein C (APC) resistance, antiphospholipid antibodies (APLA), increased factor VIII levels, and for the deficiency of protein C (PC), protein S (PS), and antithrombin. When APCR was detected in patients or in controls, factor V Leiden (FVL) mutation was also tested. Seventeen of 30 patients (56.6%) had at least one thrombophilia marker compared with only 5 of 33 control subjects (15.1%). Three children with ischemic stroke (10%) were affected with a combination of two or more thrombophilia markers whereas none of the children in the control group had a combination of risk factors. Seven of 30 children with ischemic stroke (23.3%) and one of 33 control subjects (3.03%) had APC resistance and in all of them FVL mutation were found. The prevalence of FVL mutation was higher among pediatric stroke patients than among control subjects (p < 0.05). None of the patients but one child from the control group (3.03%) had PS deficiency. Antithrombin and PC deficiencies and the presence of APLA and increased factor VIII levels were more frequent in the pediatric stroke patients than in controls but the difference was not statistically significant (p > 0.05). These data confirm that stroke in children is commonly associated with a combination of multiple risk factors and especially the prevalence of FVL mutation is increased in children with ischemic stroke compared with control subjects.en_US
dc.identifier.doi10.1177/107602960501100110
dc.identifier.endpage88en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue1en_US
dc.identifier.pmid15678277en_US
dc.identifier.scopus2-s2.0-13244260855en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage83en_US
dc.identifier.urihttps://doi.org/10.1177/107602960501100110
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21987
dc.identifier.volume11en_US
dc.identifier.wosWOS:000226858400010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIschemic Strokeen_US
dc.subjectThrombophiliaen_US
dc.subjectFactor V Leidenen_US
dc.subjectChilden_US
dc.subjectActivated Protein-Cen_US
dc.subjectFactor-Viii Levelsen_US
dc.subjectThromboembolic Complicationsen_US
dc.subjectAntiphospholipid Antibodiesen_US
dc.subjectCerebrovascular-Diseaseen_US
dc.subjectVenous Thromboembolismen_US
dc.subjectPediatric-Patientsen_US
dc.subjectClinical-Featuresen_US
dc.subjectRisk-Factorsen_US
dc.subjectChildrenen_US
dc.titleFactor V Leiden mutation and other thrombophilia markers in childhood ischemic strokeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu